Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03033914
Title A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Karmanos Cancer Institute Recruiting Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge New Jersey 07920 United States Details
Hackensack Meridian Health Recruiting Hackensack New Jersey 07601 United States Details
Memorial Sloan Kettering Monmouth Recruiting Middletown New Jersey 07748 United States Details
Memorial Sloan Kettering Bergen Recruiting Montvale New Jersey 07645 United States Details
Memorial Sloan Kettering Commack Recruiting Commack New York 11725 United States Details
Memorial Sloan Kettering Westchester Recruiting Harrison New York 10604 United States Details
Memorial Sloan Kettering Cancer Center Recruiting New York New York 10065 United States Details
Memorial Sloan Kettering Nassau Recruiting Uniondale New York 11553 United States Details
BC Cancer (Data Collection Only) Recruiting Vancouver V5Z4E6 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field